Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-04-03
2007-04-03
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S131100, C424S134100, C424S137100, C424S138100, C424S141100, C424S143100, C424S152100, C424S155100, C424S156100, C435S007100, C435S007230
Reexamination Certificate
active
09125751
ABSTRACT:
A method for killing unwanted target cells in a cell population comprising nucleated cells harvested from peripheral blood, or CD-34+ or similar early progenitor cells selected from the above nucleated cells or from bone marrow aspirates, in which method the cell population is in vitro or in vivo exposed to two or more immunotoxins selectively killing the malignant cells, is described. Furthermore the invention relates to the mixture of immunotixins, the use of the mixture and a kit for performing the method.
REFERENCES:
patent: 4219411 (1980-08-01), Yen et al.
patent: 4510244 (1985-04-01), Parks et al.
patent: 4659678 (1987-04-01), Forrest et al.
patent: 4710472 (1987-12-01), Saur et al.
patent: 4752569 (1988-06-01), Terasaki et al.
patent: 4857452 (1989-08-01), Ho
patent: 4920061 (1990-04-01), Poynton et al.
patent: 5019497 (1991-05-01), Olsson
patent: 5095097 (1992-03-01), Hermentin et al.
patent: 5185254 (1993-02-01), Linnenbach
patent: 5194300 (1993-03-01), Cheung
patent: 5219763 (1993-06-01), Van Hoegaerden
patent: 5256532 (1993-10-01), Melnicoff et al.
patent: 5264344 (1993-11-01), Sneath
patent: 5290707 (1994-03-01), Wood
patent: 5322678 (1994-06-01), Morgan, Jr. et al.
patent: 5326696 (1994-07-01), Chang
patent: 5340719 (1994-08-01), Hajek et al.
patent: 5374531 (1994-12-01), Jensen
patent: 5405784 (1995-04-01), Van Hoegaerden
patent: 5422277 (1995-06-01), Connelly et al.
patent: 5424213 (1995-06-01), Mougin
patent: 5491068 (1996-02-01), Benjamin et al.
patent: 5514340 (1996-05-01), Lansdorp et al.
patent: 5536644 (1996-07-01), Ullman et al.
patent: 5624815 (1997-04-01), Grant et al.
patent: 016 552 (1980-10-01), None
patent: 098 534 (1984-01-01), None
patent: 131 934 (1985-01-01), None
patent: 241 042 (1987-10-01), None
patent: 339 769 (1989-11-01), None
patent: 403960 (1990-06-01), None
patent: 395 355 (1990-10-01), None
patent: 537 827 (1993-04-01), None
patent: WO 90/07380 (1990-07-01), None
patent: WO 90/10692 (1990-09-01), None
patent: WO 91/01368 (1991-02-01), None
patent: WO 91/09938 (1991-07-01), None
patent: WO 91/15766 (1991-10-01), None
patent: WO 92/04961 (1992-04-01), None
patent: WO 94/07142 (1994-03-01), None
patent: WO A1 94/07139 (1994-03-01), None
patent: 95/24648 (1995-09-01), None
patent: WO 96/31777 (1996-10-01), None
Gura (Science, 278:1041-1042), 1997.
Parry et al (J. Cell Science, 101:191-199), 1997.
William P. Peters, et al.: “High-Dose Chemotherapy and Autologous Bone Marrow Support as Consolidation After Standard-Dose Adjuvant Therapy for High-Risk Primary Breast Cancer”,Journal of Oncology: Jun. 1993; vol. 11, No. 6, pp. 1132-1143.
James O. Armitage, M.D.; “Bone Marrow Transplantation”;New England Journal of Medicine; Mar. 24, 1994; vol. 330, No. 12, pp. 827-838.
Thomas J. Moss, et al.; “Contamination of Peripheral Blood Stem Cell Harvests by Circulating Neuroblastoma Cells”;Blood, 1990; vol. 76, No. 9, pp. 1879-1883.
Amy A. Ross, et al.; “Detection and Viability of Tumor Cells in Peripheral Blood Stem Cell Collections From Breast Cancer Patients Using Immunocytochemical and clonogenic Assay Techniques”;Blood; 1993; vol. 82, No. 9, pp. 2605-2610.
Malcolm K. Brenner, et al.; “Gene-marking to trace origin of relapse after autologous bone-marrow transplantation”;Lancet; 1993, pp. 85-86.
John G. Grivven, M.D., et al.; “Immunologic Purging of Marrow Assessed by PCR Before Autologous Bone Marrow Transplantation for B-Cell Lymphoma”;New England Journal of Medicine; Nov. 28, 1991; vol. 325, No. 22, pp. 1525-1533.
Elizabeth J. Shpall, et al., “Release of Tumor Cells from Bone Marrow”;Blood; Feb. 1, 1994; pp. 623-625.
Wolfram Brugger, et al.; “Mobilization of Tumor Cells and Hematopoietic Progenitor Cells Into Peripheral Blood of Patients With Solid Tumors”;Blood; 1994; vol. 83, No. 3, pp. 636-640.
Ger J. Strous, et al.; “Mucin-Type Glycoproteins”;Critical Reviews in Biochemistry and Molecular Biology; 1992; pp. 57-92.
Lou de Leij, et al.; “The Use of Monoclonal Antibodies for the Pathological Diagnosis of Lung Cancer”; In: H.H. Hansen (ed), Lung Cancer: Basic and Clinical Aspects; Boston: Martinus Niijhoff Publishers, 1986; pp. 31-48.
Aslak Godal, et al.; “Immunotoxins directed Against the High-Molecular-Weight Melanoma-Associated Antigen. Identification of Potent Antibody-Toxin Combinations”;Int. J. Cancer; 1992; pp. 631-635.
V.D. Courtenay, et al; “An In Vitro Colony Assay For Human Tumours Grown in Immune-Suppressed Mice and Treated In Vivo with Cytotoxic Agents”;Br. J. Cancer; 1978; pp. 261-268.
M.Y. Wang, et al.; “An effective immunomagnetic method for bone marrow purging in T cell malignancies”;Bone Marrow Transplantations; 1992; pp. 319-323.
Arne T. Myklebust, et al.; “Comparison of Two Antibody-based Methods for Elimination of Breast Cancer Cells from Human Bone Marrow”;Cancer Research; 1994; pp. 209-214.
Connie J. Eaves; “Peripheral Blood Stem Cells Reach New Heights”;Blood; 1993; pp. 1957-1959.
Elizabeth J. Shpall, et al.; “Transplantation of Enriched CD34-Positive Autologous Marrow Into Breast Cancer Patients Following High-Dose Chemotherapy: Influence of CD34-Positive Peripheral-Blood Progenitors and Growth Factors on Engraftment”;Journal of clinical Oncology; 1994; vol. 12, No. 1, pp. 28-36.
Michael J. Bjorn, et al.; “Antibody-Pseudomonas Exotoxin A Conjugates to Human Breast Cancer Cells in Vitro”;Cancer Research; Jul. 1986; pp. 3262-3267.
1989 Ian c. Anderson, et al.; “Elimination of Malignant Clonogenic Breast Cancer Cells from Human Bone Marrow”;Cancer Research; pp. 4659-4664.
K.C. O-Briant, MS, et al.; Elimination of Clongenic Breast Cancer Cells from Human Bone Marrow ;Cancer; 1991; pp. 1272-1278.
C.L. Tyer, et al.; “Breast Cancer Cells are Effectively Purged from Peripheral Blood Progenitor cells Using an Immunomagnetic Technique”; Abstract to First meeting of International Society for Hematotherapy and Graft Engineering, Orlando, Fl, 1993.
Firoenzo Stirpe, et al.; “Ribosome-Inactivating Proteins from Plants: Present Status and future Prospects”;Bio/Technology, Apr. 1992; vol. 10, pp. 405-412.
Luigi Barbieri, et al.; “Ribosome-inactivating proteins from plants”;Biochimica et Biophysica Acta; 1993; pp. 237-282.
R.M. Lemoli, et al.; “Positive selection of hematopoietic CD34+ stem cells provides ‘indirect purging’ of CD34-lymphoid cells and the purging efficiency is increased by anti-CD2 and anti-CD30 immunotoxins”;Bone Marrow Transplantation; 1994; pp. 465-471.
I.J. Diel, et al.; “Detection of Tumor Cells in Bone Marrow of Patients with Primary Breast Cancer: A Prognostic Factor for Distant Metastasis”;Journal of Clinical Oncology; 1992; pp. 1534-1539.
Arne T. Muklebust , et al.; “Eradication of Small Cell Lung Cancer Cells from Human Bone Marrow with Immunotoxins”;Cancer Research; 1993; pp. 3784-3788.
K.M. Stray, et al.; “Purging Tumor Cells from Bone Marrow or Peripheral Blood Using Avidin-Biotin Immunoadsorption”;Advances in Bone Marrow Purging and Processing; 1994; Orlando:Wiley-Liss, Inc.; pp. 97-103.
D. Pilling, et al.; “The kinetics of interaction between lymphocytes and magnetic polymer particles”;National Library of Medicine, File Medline, Medline accession No. 90010165; Sep. 1, 1989; 122(2) pp. 235-241.
R.M. Leven, et al.,; “Immunomagnetic bead isolation of megakaryocytes from guinea-pig bone marrow: effect of recombinant interleukin-6 on size, ploidy and cytoplasmic fragmentation”;National Library of Medicine, File Medline, Medline accession No. 07671620; Br J Haematol Mar. 1991; 77 (3), pp. 267-273.
Jan. 1993, Bio/Technology, vol. 11, Bjorn-Ivar Haukanes et al., “Application of Magnetic Beads in Bioassays” p. 60.
1990, Scand J. Immunol, vol. 31, J. Heldrup, “A New Technique Using an Aggregating Antibody Against G
Engebraten Olav
Fodstad Oystein
Juell Siri
Kvalbeim Gunnar
Wang Meng yu
Merchant & Gould P.C.
Oystein Fodstad
Ungar Susan
LandOfFree
Method of killing target cells in harvested cell populations... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of killing target cells in harvested cell populations..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of killing target cells in harvested cell populations... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3726826